Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other financing activities (2020 - 2024)

Tarsus Pharmaceuticals has reported Other financing activities over the past 3 years, most recently at $39000.0 for Q3 2024.

  • Quarterly results put Other financing activities at $39000.0 for Q3 2024, changed N/A from a year ago — trailing twelve months through Dec 2025 was $39000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $3.5 million, changed.
  • Other financing activities for Q3 2024 was $39000.0 at Tarsus Pharmaceuticals, down from $60000.0 in the prior quarter.
  • Over the last five years, Other financing activities for TARS hit a ceiling of $2.1 million in Q4 2020 and a floor of $1000.0 in Q2 2020.
  • Median Other financing activities over the past 3 years was $60000.0 (2022), compared with a mean of $471000.0.